Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00351325 · ClinicalTrials.gov registry record · Phase 1

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

A Phase 1 study, sponsored by Bristol-Myers Squibb.

Terminated
Registry status
Phase 1
Development phase
45
Enrollment target

NCT00351325: Clinical Trial Phase 1 study, sponsored by Bristol-Myers Squibb.

NCT00351325 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 45 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00351325, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.

TERMINATED
Registry status
Phase 1
Development phase
45 participants
Enrollment target

Study Summary

The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.

Interventions

  • DRUG BMS-663513

Trial Details

FieldValue
Enrollment Target 45 participants
Start Date 2007-09
Est. Completion 2009-03
Phase Phase 1
Bristol-Myers Squibb

1,025 total trials

Why NCT00351325 stopped before completion

NCT00351325 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 45 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (25% lower).

The record links to 0 conditions, and to 1 intervention - of which BMS-663513 is the first listed.

NCT00351325 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00351325 about?

NCT00351325 is a clinical study titled "A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies". The purpose of this study is to assess the safety and tolerability of multiple escalating doses of BMS-663513 when given in combination with paclitaxel and carboplatin.

What is the current status of trial NCT00351325?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 45 participants. The study started on 2007-09. Estimated completion is 2009-03.

What interventions are being tested in trial NCT00351325?

The interventions under investigation include: BMS-663513 (DRUG).

Who is sponsoring clinical trial NCT00351325?

This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00351325's enrollment target sits among peer trials

45 1066th of 2000 higher than 915 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00804154 · 45 participants · Phase 1

    Resiniferatoxin to Treat Severe Pain Associated With Advanced Cancer

  • NCT01851694 · 45 participants · NA

    Beta-cell Response to Incretin Hormones in Cystic Fibrosis

  • NCT02896335 · 45 participants · Phase 2

    Palbociclib and Pembrolizumab In Central Nervous System Metastases

  • NCT03454035 · 45 participants · Phase 1

    Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00351325, the US trial registry maintained by the National Library of Medicine. NCT00351325 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.